Orthofix TraumaJet
This article was originally published in The Gray Sheet
Executive Summary
Ultrahigh-pressure, fluidjet-based wound debridement system made by HydroCision for distribution by Orthofix gains FDA market go-ahead. The device removes contamination and dead and damaged tissue with minimal risk of spreading infection, requires less sterile fluid than conventional irrigation devices, and has a $100 mil. worldwide market potential, according to Orthofix. Over 1,000 surgeons worldwide have been trained during the last year
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.